Angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical treatment: One-year interim results of SPACE-2.
Tilman ReiffH H EcksteinU MansmannO JansenG FraedrichH MudraD BöcklerM BöhmH BrückmannE S DebusJ FiehlerW LangK MathiasE B RingelsteinJ SchmidliR StingeleR ZahnT ZellerA HetzelU BodechtelA BinderJ GlahnW HackeP A RinglebPublished in: International journal of stroke : official journal of the International Stroke Society (2019)
The low sample size of this prematurely stopped trial of 513 patients implies that its power is not sufficient to show that CEA or CAS is superior to a modern medical therapy (BMT) in the primary prevention of ischemic stroke in patients with an asymptomatic carotid stenosis up to one year after treatment. Also, no evidence for differences in safety between CAS and CEA during the first year after treatment could be derived. Follow-up will be performed up to five years. Data may be used for pooled analysis with ongoing trials.
Keyphrases
- crispr cas
- end stage renal disease
- healthcare
- genome editing
- ejection fraction
- newly diagnosed
- chronic kidney disease
- clinical trial
- peritoneal dialysis
- prognostic factors
- study protocol
- atrial fibrillation
- phase iii
- big data
- coronary artery disease
- patient reported outcomes
- bone marrow
- acute coronary syndrome
- artificial intelligence
- placebo controlled